PM 50/JSB

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

SEP 15 1989

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

Subject: Diazinon: Multiresidue Protocol Data, DEB No. 5452, HED No. 9-1626, MRID No. 410726-02

From: Elizabeth T. Haeberer, Chemist
Dietary Exposure Branch
Health Effects Division (H7509C)

Thru: Debra F. Edwards, Ph.D., Section Chief
Tolerance Petition Section II
Dietary Exposure Branch
Health Effects Division (H7509C)

To: J. Edwards, PM Team 74
Reregistration Branch
Special Review & Reregistration Division (H7508C)

BACKGROUND

Ciba-Geigy Corporation, registrant of products containing diazinon as active ingredient, has submitted the following multiresidue test data in accordance with the protocols set forth in the FDA Pesticide Analytical Manual, Volume I, (PAM I), Appendix II:

> "Determination of Diazinon and its Major Metabolites by U.S. Food and Drug Administration (FDA) Multiresidue Protocols I, II, III, and IV", by R.K. Williams (author), Ceiba-Geigy Corporation, Greensboro, NC (sponsor), Sponsor Study No. ABR-88125, Ciba-Geigy Corporation (performing laboratory), 4/17/89, 141 pages, MRID No. 410726-02.

These data were submitted in response to a data gap listed in the Diazinon Registration Standard, dated 8/6/86.

DISCUSSION

Ciba-Geigy has submitted a study (MRID No. 410726-02) that evaluates the detection of diazinon and 4 of its metabolites (G-24576, CGA-14128, G-27550, and GS-31144) under the appropriate FDA Multiresidue Methodology (MRM) Testing Protocols. The metabolites have been identified as follows:

G-24576	diazoxon
CGA-14128	hydroxydiazinon
G-27550	diazinon hydroxypyrimidine
GS-31144	2-(1-hydroxyisopropyl)-4-methyl-6-hydroxypyrimidine

To summarize the results, Multiresidue Protocol III is the most appropriate for the determination of diazinon, G-24576, G-27550, and CGA-14128 in plant commodities and animal tissues. None of the multiresidue methods are adequate for the determination of the metabolite GS-31144.

This study is being forwarded to FDA for evaluation/inclusion in a future updating of PAM I.

CONCLUSIONS

Barring a request for additional information from FDA, EPA will consider this study sufficient to fulfill the data requirement for MRM testing of the Diazinon Registration Standard.

cc: E. Haeberer, RF, Circ. (7), Diazinon Reistration Std. File,
M. Bradley, R. Schmitt, PMSD/ISB (E. Eldredge).
RDI: D. Edwards, 9/15/89; R. Loranger, 9/15/89
eth

2